The frequency of anti-tumor CD4 TRB clonotypes was 12.7-fold higher in host peritoneum than host spleen and 7.9-fold higher for CD8 TRB clonotypes, confirming our previous work, that anti-tumor memory CD4 and CD8 T-cells migrate to and expand at the site of challenge in tumor-cured mice (5, 11). This evidence concerns the gene CD4 and neoplasm.